|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 11.28 USD | -0.62% |
|
+5.82% | -44.60% |
| 09-29 | Keros Therapeutics Expects $20 Million Milestone Payment From Takeda | MT |
| 09-29 | Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KEROS THERAPEUTICS, INC. | Bio Therapeutic Drugs | -0.62% | +5.82% | -44.60% | -24.19% | -70.94% | 225M |  | |  |
- Stock Market
- Stocks
- KROS Stock
- Charts Keros Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
